KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $136.5 million.

  • Biomarin Pharmaceutical's Cash from Investing Activities fell 1948.42% to -$331.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.4 million, marking a year-over-year decrease of 5958.02%. This contributed to the annual value of $136.5 million for FY2024, which is 222.70% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's Cash from Investing Activities stood at $136.5 million, which was up 222.70% from -$111.2 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Cash from Investing Activities registered a high of $136.5 million during FY2024, and its lowest value of -$366.3 million during FY2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$20.0 million (2022), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Cash from Investing Activities plummeted by 583.15% in 2021, and later spiked by 222.70% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash from Investing Activities (Yearly) stood at -$53.6 million in 2020, then slumped by 583.15% to -$366.3 million in 2021, then surged by 94.53% to -$20.0 million in 2022, then tumbled by 455.41% to -$111.2 million in 2023, then spiked by 222.70% to $136.5 million in 2024.